Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
Open Access
- 23 February 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2259
- https://doi.org/10.3390/ijms22052259
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of bone marrow (BM) clonal plasma cells, which are strictly dependent on the microenvironment. Despite the improvement of MM survival with the use of new drugs, MM patients still relapse and become always refractory to the treatment. The development of new therapeutic strategies targeting both tumor and microenvironment cells are necessary. Oncolytic virotherapy represent a promising approach in cancer treatment due to tumor-specific oncolysis and activation of the immune system. Different types of human viruses were checked in preclinical MM models, and the use of several viruses are currently investigated in clinical trials in MM patients. More recently, the use of alternative non-human viruses has been also highlighted in preclinical studies. This strategy could avoid the antiviral immune response of the patients against human viruses due to vaccination or natural infections, which could invalid the efficiency of virotherapy approach. In this review, we explored the effects of the main oncolytic viruses, which act through both direct and indirect mechanisms targeting myeloma and microenvironment cells inducing an anti-MM response. The efficacy of the oncolytic virus-therapy in combination with other anti-MM drugs targeting the microenvironment has been also discussed.Funding Information
- Ministero della salute italiana (PE-2016-02361261)
- Associazione Italiana per la Ricerca sul Cancro (IG2017 20299)
This publication has 108 references indexed in Scilit:
- LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virusProceedings of the National Academy of Sciences of the United States of America, 2013
- Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-βCancer Gene Therapy, 2012
- Curative one-shot systemic virotherapy in murine myelomaLeukemia, 2012
- Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and FutureBone Marrow Research, 2011
- Infection and Killing of Multiple Myeloma by AdenovirusesHuman Gene Therapy, 2010
- Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer TherapyMolecular Therapy, 2009
- Tumor‐associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myelomaAmerican Journal of Hematology, 2009
- Junctional Adhesion Molecule-A Is Required for Hematogenous Dissemination of ReovirusCell Host & Microbe, 2009
- Oncolytic viruses: a novel form of immunotherapyExpert Review of Anticancer Therapy, 2008
- Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter geneBlood, 2007